Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharmaceutical Industries Ltd.

www.sunpharma.com

Latest From Sun Pharmaceutical Industries Ltd.

Japan Nods Include Global First For Duvroq, First Local Biosimilar Humira

Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.

Japan Approvals

Sun And Hikma Strike Ilumya Deal

Sun has inked another commercial partnership to bring psoriasis drug Ilumya to countries outside India, this time teaming with Hikma in the MENA region.

Deals Strategy

OTC Decisions In May: Esomeprazole For Sun Pharma, Guaifenesin For Granules India, More NRTs For PLD During Slow Month For Approvals

CDER representative says staff’s time available for drug applications currently is affected by the FDA having employees work remotely in response to the novel coronavirus pandemic.

OTC Drugs FDA

Four Digital Saviors Of Indian Pharma During COVID-19

From digital marketing to payment systems, electronic solutions are aiding Indian pharma to ensure business continuity during the lockdown. New guidelines are spurring the adoption of telemedicine. Digital tools are connecting companies to their distribution chains and health care professionals. While some changes are here to stay, others might not stick.

Telehealth India
See All

Company Information

UsernamePublicRestriction

Register